홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
OKYO
#6046
OKYO Pharma Limited Ordinary Shares
1.7
1
0.00%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
0.00%
월간 변동
-23.32%
6달 변화
-24.67%
년간 변동율
+44.92%
이전 종가
1.7
1
Open
1.7
1
Bid
Ask
Low
1.7
1
High
1.7
1
양
2
마켓
주식
헬스케어
OKYO
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
2021
2022
2023
2024
TTM
Key stats
Total common shares outstanding
1.37 B
25.55 M
33.84 M
37.61 M
—
Valuation ratios
Enterprise value
—
—
48.91 M
43.17 M
—
Price to earnings ratio
—
—
—
—
—
Price to sales ratio
—
—
—
—
—
Price to cash flow ratio
—
—
—
—
—
Price to book ratio
—
—
—
—
—
Enterprise value to EBITDA ratio
—
—
—
—
—
Profitability ratios
Return on assets %
-1.26
2.56
10.9
1.28
—
Return on equity %
-1.84
-6.48
-2.86
-0.85
—
Return on invested capital %
—
—
—
—
—
Gross margin %
—
—
—
100
—
Operating margin %
—
—
—
-38.54 K
—
EBITDA margin %
—
—
—
—
—
Net margin %
—
—
—
85.88 K
—
Liquidity ratios
Quick ratio
—
—
—
—
—
Current ratio
3.17
0.72
0.21
0.4
—
Inventory turnover
—
—
—
—
—
Asset turnover
0
0
0
0
—
Solvency ratios
Debt to assets ratio
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
—
—
—
EBIT per share
—
—
—
—
—
EBITDA per share
—
—
—
—
—
Total debt per share
—
—
—
—
—
Cash per share
—
—
—
—
—
Net current asset value per share
—
—
—
—
—
Tangible book value per share
—
—
—
—
—
Working capital per share
—
—
—
—
—
Book value per share
—
—
—
—
—
뉴스
OKYO Pharma, Piper Sandler ’비중확대’ 투자의견 제시
Piper Sandler initiates OKYO Pharma stock with Overweight rating
OKYO Pharma, 2천만 달러 규모 공모 발표 후 주가 급락
OKYO Pharma stock tumbles on $20 million public offering announcement
OKYO 파마, 보통주 2천만 달러 규모 공모 발표
OKYO Pharma announces $20 million public offering of ordinary shares
OKYO 파마, ATM 주식 공모 판매 대행사 Leerink Partners로 변경
OKYO Pharma transitions ATM equity offering to Leerink Partners as sales agent
OKYO 파마, 플라비오 만텔리 전 Dompé CMO 임명
OKYO Pharma appoints former Dompé CMO Flavio Mantelli to lead NCP program
OKYO 파마, ASCRS서 Urkosimod NCP 연구 결과 발표 예정
OKYO Pharma to present urcosimod NCP study results at ASCRS meeting